Advancing the growth of Georgia's life sciences industry.

Learn More

Georgia Bio announced that it has rebranded the organization as Georgia Life Sciences, bringing renewed focus and support to the core strengths of the business and academic organizations within Georgia’s life sciences and healthcare communities.

As the leading advocate for the state’s dynamic and diverse life sciences sector, Georgia Life Sciences promotes policy development, community programs, industry initiatives, and events, as well as the research and products of its associated member and partner organizations.

Policy & Advocacy

Advance life sciences innovation through policy and advocacy leadership at all levels of government

Workforce & Talent

Establish Georgia as a center for excellence in life science workforce training and talent development

Economic Development

Provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in Georgia

Entrepreneurship

Serve as catalyst for life sciences innovation by helping entrepreneurs build successful ventures

Networking

Foster connection by convening thought leaders around relevant industry topics and peer-to-peer exchange opportunities

Cost Savings

Curated discounts on products and services critical to running a successful business

Upcoming Events

View Calendar

Biotechnology Advocates Press Congress for R&D Tax Reform

By Sheran Brown • April 1, 2025

In a coordinated effort on the national stage, Georgia Life Sciences is joining forces with 47 other state biotechnology associations under the Council of State Biosciences Associations (CSBA) umbrella to urge congressional action on research and development tax amortization legislation. The coalition has sent a formal letter to congressional leadership calling for the immediate passage of the American Innovation and R&D Competitiveness Act (H.R. 1990), bipartisan legislation sponsored by Representatives Ron Estes (D-KS) and John Larson (R-CT). The bill aims to repeal harmful research and amortization provisions that went into effect in 2022 under the Tax Cuts and Jobs Act. Georgia Life Sciences representatives are heading to Washington DC this week alongside fellow CSBA members to meet directly with Georgia legislators. The group will advocate for this critical tax reform, which would restore immediate expensing of R&D expenditures rather than requiring companies to amortize these deductions over five years for domestic expenditures or 15 years for foreign expenditures. The current mandatory amortization requirements are "already diverting much-needed funds away from small R&D-intensive companies, potentially jeopardizing the development of future treatments and negatively impacting the local economies where these companies are established," according to the CSBA letter. During their Capitol Hill visits, the Georgia Life Sciences delegation will also address other pressing issues facing Georgia’s life sciences community while emphasizing the importance of supporting innovation in an industry dominated by pre-revenue companies developing critical medical breakthroughs.

FDA Vaccine Chief Resigns, Citing Concerns Over Kennedy's Stance on Vaccines; BIO Statement

By Sheran Brown • April 1, 2025

The Food and Drug Administration's top vaccine official, Dr. Peter Marks, has resigned under pressure, directly criticizing Health Secretary Robert F. Kennedy Jr.'s approach to vaccine policy in his departure. In his resignation letter to Acting FDA Commissioner Sara Brenner, Marks wrote: "It has become clear that truth and transparency are not desired by the secretary, but rather he wishes subservient confirmation of his misinformation and lies." Marks was reportedly given the option to resign or be fired during a meeting at the Department of Health and Human Services on Friday. In a subsequent interview, Marks reinforced his concerns, stating: "This man doesn't care about the truth. He cares about what is making him followers." John F. Crowley, president and CEO of the Biotechnology Innovation Organization (BIO) , praised Marks' tenure in a statement following the announcement: "Under the extraordinary leadership of Dr. Peter Marks, the FDA shepherded in a new era of scientific breakthroughs -- from new vaccines to curative cell and gene therapies that have strengthened and saved the lives of millions of patients and families." Crowley expressed concern about potential ramifications for healthcare innovation, noting: "We are deeply concerned that the loss of experienced leadership at the FDA will erode scientific standards and broadly impact the development of new, transformative therapies to fight diseases for the American people." BIO emphasized its commitment to working with the new Commissioner and administration while stressing the importance of upholding scientific expertise and high standards at health institutions.

View All News

Registration now open

August 26-27, 2025

Sandy Springs Performing Arts Center

Member Benefits

Be Part of Our Growing Community

By joining Georgia Life Sciences, you will be part of a vibrant community that is making significant strides in growing the bioscience industry in our state. We conduct economic development activities; advocates on behalf its members on public policy matters; educates the public about the benefits of life sciences research and product development; and provides a network for idea exchange and cooperation.

Join

Renew

Leverage the Power of Georgia Life Sciences: Become a Sponsor

Georgia Life Sciences’ sponsorships unlock unparalleled access and influence within the state’s life sciences industry. Go beyond traditional event sponsorships and engage directly with a multifaceted ecosystem through our combined reach across exclusive programming, key initiatives, events, media channels, and industry association networks.

DOWNLOAD

Why Join Georgia Life Sciences?

Membership in Georgia Life Sciences connects you with all facets of

our sector and helps cement your place in a community that shares the vision of improved health and a better world. We are the unified voice among key stakeholders and leading convenor for partnerships and strategic collaborations.

Learn More